Literature DB >> 23602993

NCL diseases - clinical perspectives.

Angela Schulz1, Alfried Kohlschütter, Jonathan Mink, Alessandro Simonati, Ruth Williams.   

Abstract

The neuronal ceroid lipofuscinoses (NCLs) are lysosomal storage disorders and together are the most common degenerative brain diseases in childhood. They are a group of disorders linked by the characteristic accumulation of abnormal storage material in neurons and other cell types, and a degenerative disease course. All NCLs are characterized by a combination of dementia, epilepsy, and motor decline. For most childhood NCLs, a progressive visual failure is also a core feature. The characteristics of these symptoms can vary and the age at disease onset ranges from birth to young adulthood. Genetic heterogeneity, with fourteen identified NCL genes and wide phenotypic variability render diagnosis difficult. A new NCL classification system based on the affected gene and the age at disease onset allows a precise and practical delineation of an individual patient's NCL type. A diagnostic algorithm to identify each NCL form is presented here. Precise NCL diagnosis is essential not only for genetic counseling, but also for the optimal delivery of care and information sharing with the family and other caregivers. These aspects are challenging because there are also potential long term complications which are specific to NCL type. Therefore care supported by a specifically experienced team of clinicians is recommended. As the underlying pathophysiological mechanism is still unclear for all NCL forms, the development of curative therapies remains difficult. This article is part of a Special Issue entitled: The neuronal ceroid lipofuscinoses or Batten Disease.
Copyright © 2013. Published by Elsevier B.V.

Entities:  

Keywords:  Batten; Ceroid; Diagnostic algorithm; Disease classification; NCLs

Mesh:

Year:  2013        PMID: 23602993      PMCID: PMC4631127          DOI: 10.1016/j.bbadis.2013.04.008

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  21 in total

1.  Identifying and managing sources of pain and distress in children with neurological impairment.

Authors:  Julie Hauer
Journal:  Pediatr Ann       Date:  2010-04       Impact factor: 1.132

2.  Analysis of potential biomarkers and modifier genes affecting the clinical course of CLN3 disease.

Authors:  Anne-Hélène Lebrun; Parisa Moll-Khosrawi; Sandra Pohl; Georgia Makrypidi; Stephan Storch; Dirk Kilian; Thomas Streichert; Benjamin Otto; Sara E Mole; Kurt Ullrich; Susan Cotman; Alfried Kohlschütter; Thomas Braulke; Angela Schulz
Journal:  Mol Med       Date:  2011-08-18       Impact factor: 6.354

3.  Mutations in DNAJC5, encoding cysteine-string protein alpha, cause autosomal-dominant adult-onset neuronal ceroid lipofuscinosis.

Authors:  Lenka Nosková; Viktor Stránecký; Hana Hartmannová; Anna Přistoupilová; Veronika Barešová; Robert Ivánek; Helena Hůlková; Helena Jahnová; Julie van der Zee; John F Staropoli; Katherine B Sims; Jaana Tyynelä; Christine Van Broeckhoven; Peter C G Nijssen; Sara E Mole; Milan Elleder; Stanislav Kmoch
Journal:  Am J Hum Genet       Date:  2011-08-04       Impact factor: 11.025

4.  Late infantile neuronal ceroid lipofuscinosis: quantitative description of the clinical course in patients with CLN2 mutations.

Authors:  Robert Steinfeld; Peter Heim; Henning von Gregory; Kerstin Meyer; Kurt Ullrich; Hans H Goebel; Alfried Kohlschütter
Journal:  Am J Med Genet       Date:  2002-11-01

5.  Northern epilepsy: a novel form of neuronal ceroid-lipofuscinosis.

Authors:  R Herva; J Tyynelä; A Hirvasniemi; M Syrjäkallio-Ylitalo; M Haltia
Journal:  Brain Pathol       Date:  2000-04       Impact factor: 6.508

Review 6.  Infantile neuronal ceroid-lipofuscinosis (INCL): diagnostic criteria.

Authors:  P Santavuori; S L Vanhanen; K Sainio; M Nieminen; T Wallden; J Launes; R Raininko
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

Review 7.  Kufs disease: clinical features and forms.

Authors:  S F Berkovic; F Andermann; E Andermann; S Carpenter; L Wolfe
Journal:  Am J Med Genet Suppl       Date:  1988

8.  Retention of lysosomal protein CLN5 in the endoplasmic reticulum causes neuronal ceroid lipofuscinosis in Asian sibship.

Authors:  Anne-Hélène Lebrun; Stephan Storch; Franz Rüschendorf; Mia-Lisa Schmiedt; Aija Kyttälä; Sara E Mole; Claudia Kitzmüller; Kathrin Saar; Leena D Mewasingh; Volker Boda; Alfried Kohlschütter; Kurt Ullrich; Thomas Braulke; Angela Schulz
Journal:  Hum Mutat       Date:  2009-05       Impact factor: 4.878

Review 9.  Update of the mutation spectrum and clinical correlations of over 360 mutations in eight genes that underlie the neuronal ceroid lipofuscinoses.

Authors:  Maria Kousi; Anna-Elina Lehesjoki; Sara E Mole
Journal:  Hum Mutat       Date:  2011-11-16       Impact factor: 4.700

10.  Mutation of the parkinsonism gene ATP13A2 causes neuronal ceroid-lipofuscinosis.

Authors:  Jose Bras; Alain Verloes; Susanne A Schneider; Sara E Mole; Rita J Guerreiro
Journal:  Hum Mol Genet       Date:  2012-03-02       Impact factor: 6.150

View more
  68 in total

1.  Abnormally increased surface expression of AMPA receptors in the cerebellum, cortex and striatum of Cln3(-/-) mice.

Authors:  Attila D Kovács; Caitlin Hof; David A Pearce
Journal:  Neurosci Lett       Date:  2015-09-12       Impact factor: 3.046

2.  Neuronal ceroid lipofuscinosis: genetic and phenotypic spectrum of 14 patients from Turkey.

Authors:  Melis Kose; Engin Kose; Aycan Ünalp; Ünsal Yılmaz; Selvinaz Edizer; Hande Gazeteci Tekin; Pakize Karaoğlu; Taha Reşid Özdemir; Esra Er; Hüseyin Onay; Eser Sozmen Yildirim
Journal:  Neurol Sci       Date:  2021-01-23       Impact factor: 3.307

3.  Upregulation of tripeptidyl-peptidase 1 by 3-hydroxy-(2,2)-dimethyl butyrate, a brain endogenous ligand of PPARα: Implications for late-infantile Batten disease therapy.

Authors:  Sudipta Chakrabarti; Sujyoti Chandra; Avik Roy; Sridevi Dasarathi; Madhuchhanda Kundu; Kalipada Pahan
Journal:  Neurobiol Dis       Date:  2019-03-28       Impact factor: 5.996

Review 4.  The best evidence for progressive myoclonic epilepsy: A pathway to precision therapy.

Authors:  Alessandro Orsini; Angelo Valetto; Veronica Bertini; Mariagrazia Esposito; Niccolò Carli; Berge A Minassian; Alice Bonuccelli; Diego Peroni; Roberto Michelucci; Pasquale Striano
Journal:  Seizure       Date:  2019-08-23       Impact factor: 3.184

Review 5.  Drug Treatment of Progressive Myoclonic Epilepsy.

Authors:  Gregory L Holmes
Journal:  Paediatr Drugs       Date:  2020-04       Impact factor: 3.022

6.  Phenotyping heterozygous carriers of juvenile neuronal ceroid lipofuscinosis with CLN3 mutations.

Authors:  Richard Bergholz; Alfried Kohlschütter; Angela Schulz; Waltraud Hubert; Klaus Rüther
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-10-22       Impact factor: 3.117

7.  Gene Therapy Targeting the Inner Retina Rescues the Retinal Phenotype in a Mouse Model of CLN3 Batten Disease.

Authors:  Sophia-Martha Kleine Holthaus; Mikel Aristorena; Ryea Maswood; Olha Semenyuk; Justin Hoke; Aura Hare; Alexander J Smith; Sara E Mole; Robin R Ali
Journal:  Hum Gene Ther       Date:  2020-07       Impact factor: 5.695

8.  Electroclinical spectrum of the neuronal ceroid lipofuscinoses associated with CLN6 mutations.

Authors:  Laura Canafoglia; Isabella Gilioli; Federica Invernizzi; Vito Sofia; Valeria Fugnanesi; Michela Morbin; Luisa Chiapparini; Tiziana Granata; Simona Binelli; Vidmer Scaioli; Barbara Garavaglia; Nardo Nardocci; Samuel F Berkovic; Silvana Franceschetti
Journal:  Neurology       Date:  2015-06-26       Impact factor: 9.910

9.  Aberrant adhesion impacts early development in a Dictyostelium model for juvenile neuronal ceroid lipofuscinosis.

Authors:  Robert J Huber; Michael A Myre; Susan L Cotman
Journal:  Cell Adh Migr       Date:  2016-09-26       Impact factor: 3.405

10.  Manifestation of neuronal ceroid lipofuscinosis in Australian Merino sheep: observations on altered behaviour and growth.

Authors:  Greg M Cronin; Danai F Beganovic; Amanda L Sutton; DavidJ Palmer; Peter C Thomson; Imke Tammen
Journal:  Appl Anim Behav Sci       Date:  2016-02-01       Impact factor: 2.448

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.